Integrum Partners with Onkos Surgical to Further Drive US Market for Bone-Anchored Prosthetics

Onkos Surgical to distribute Integrum’s revolutionary osseointegration products to select surgical centers in the US market, further expanding market presence for Integrum.

Mölndal, Sweden (January 21, 2020) –  Integrum and Onkos Surgical have entered into a multi-year collaboration focused on the US market.  Integrum’s OPRA™ Implant System is an innovative technology aimed at helping improve the quality of life for amputees.  Together Integrum and Onkos Surgical aim to increase adoption for bone-anchored prosthetic technology in key US surgical centers. 

“We are pleased to partner with a world-class company like Onkos Surgical for the benefit of the US market.  I’m convinced that together Integrum and Onkos can accelerate adoption of the OPRA™ technology, providing more options for amputees wanting to take advantage of this remarkable technology,” remarked Maria Lopez, Integrum’s CEO.

Onkos Surgical was founded in 2015 with a singular focus on bringing innovation to musculoskeletal oncologists and the patients they care for.  Built on a digital platform, Onkos is an emerging leader in the field of personalized orthopaedics.  With expertise in personalized surgical planning, 3D modeling and the latest advancements in 3D printing, the company has developed a suite of products designed to reduce complexity and address the clinical challenges associated with tumor and complex orthopedic revision surgery.   Patrick Treacy, Co-founder and CEO said, “We are delighted to partner with Dr. Rickard Brånemark, a global expert and leading pioneer in the field of osseointegration.  Integrum is revolutionizing the field of bone anchored prosthetics and given our focus on limb salvage, the OPRA™ technology is complementary to our portfolio strategy.  The combined expertise of both companies will provide surgeons with greater access to advanced bone anchored prosthetics and provide patients with meaningful reconstructive options.”

The OPRA Implant System consists of an anchorage element fixture and a skin penetrating device abutment The prosthetic leg is then attached directly to the abutment via the OPRAT AXOR a prosthetic connection and safety device 

The OPRA™ Implant System consists of an anchorage element (fixture) and a skin penetrating device (abutment). The prosthetic leg is then attached directly to the abutment via the OPRAT™ AXOR™, a prosthetic connection and safety device.-

Integrum’s OPRA™ (Osseoanchored Prostheses for the Rehabilitation of Amputees) Implant System is the only FDA-approved, bone-anchored prosthetic solution available in the United States. OPRA™ consists of an anchorage element (fixture) and a skin penetrating device (abutment).  The fixture is surgically inserted into the femur and after a healing time of several months the abutment is connected to the fixture.  The prosthetic leg is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.

Cautions Concerning Forward-Looking Statements

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “future,” “believes,” “expects,” “may,” “will,” “can,” “should,” “potential,” “estimates,” “intends,” “aims,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations but are subject to known and unknown risks and uncertainties including, without limitation, delays potentially caused by the need for institutional review board approval and product training, distribution challenges, unexpected product efficacy and safety concerns, product or raw material availability and other supply constraints.  Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results. The forward-looking statements included are made only as the date of this release. The company assumes no obligation to update any information or forward-looking statement contained herein, save for any information required to be disclosed by law.

The information in this press release is information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 08:00 CET on Jan 21, 2020.

Integrum AB is listed on Nasdaq First North in Stockholm. Erik Penser is the Company´s Certified Adviser.

About Integrum

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden with a U.S. subsidiary in San Francisco, CA. Since 1990 osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations towards an improved quality of life. A thorough surgical experience gained over two decades has led to development of Integrum’s system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum is the worldwide scientific and thought leader in this area treating hundreds of patients from all parts of the world including clinical centers in the US.  Integrum’s OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the US under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA-approved technology for bone-anchored prosthetics available in the US. More information on the company and its innovative solutions for amputees can be found at

About Onkos Surgical

Based in Parsippany, N.J., Onkos Surgical is a privately held surgical oncology company founded in 2015. We believe that individuals with cancer requiring surgery deserve solutions designed specifically for them.  This principle is the driving force behind our Precision Oncology initiatives.  Built on a digital platform, our solutions are rooted in unmatched expertise in patient imaging analysis, personalized surgical planning, and the latest advancements in 3D printing.  At Onkos, we are passionate about reducing complexity for our customers and addressing the clinical challenges associated with tumor surgery.


Maria Lopez
Integrum AB
+46 708 46 10 69

Sean P. Curry
SVP, Commercial Operations
Onkos Surgical
+1 (973) 264-5400

An OPRA Implant System amputee user showing the connection of a standard prosthetic leg to the OPRA Implant System via the OPRA AXOR prosthetic connection and safety device

An OPRA™ Implant System amputee user, showing the connection of a standard prosthetic leg to the OPRA™ Implant System via the OPRA™ AXOR™ prosthetic connection and safety device.